KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to $10.4 million.

  • Guardant Health's Capital Expenditures rose 14648.73% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year increase of 9388.28%. This contributed to the annual value of $35.1 million for FY2024, which is 7126.33% up from last year.
  • Per Guardant Health's latest filing, its Capital Expenditures stood at $10.4 million for Q3 2025, which was up 14648.73% from $5.6 million recorded in Q2 2025.
  • Guardant Health's 5-year Capital Expenditures high stood at $24.6 million for Q4 2021, and its period low was $2.4 million during Q3 2023.
  • In the last 5 years, Guardant Health's Capital Expenditures had a median value of $9.6 million in 2021 and averaged $12.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 8908.22% in 2023, then skyrocketed by 36296.3% in 2024.
  • Quarter analysis of 5 years shows Guardant Health's Capital Expenditures stood at $24.6 million in 2021, then crashed by 59.39% to $10.0 million in 2022, then tumbled by 59.23% to $4.1 million in 2023, then surged by 362.96% to $18.9 million in 2024, then plummeted by 45.17% to $10.4 million in 2025.
  • Its Capital Expenditures stands at $10.4 million for Q3 2025, versus $5.6 million for Q2 2025 and $4.5 million for Q1 2025.